

R. PHILIP EATON, M. D.

University of New Mexico Health Sciences Center  
Office of the Vice President  
Albuquerque, NM 87131-5001  
(505) 272-5849, Fax: (505) 272-3601

---

EDUCATION:

College: 1953-1957	The College of Wooster, Wooster, Ohio, Bachelor Arts Degree, Honors in Chemistry; Major in Chemistry, Minor in Biology, Cunningham Memorial Award for Outstanding Pre-med student
Medical School: 1957-1961	University of Chicago Medical School Cum laude Alpha Omega Alpha

ACADEMIC APPOINTMENTS – UNIVERSITY OF NEW MEXICO:

May 2002 – present	Vice President for Health Sciences
December 1998 – May 2002	Interim Vice President for Health Sciences
December 1997 - December 1998 January 1996 – December 1998	Associate Director, Clinical Research Center Associate Dean for Research
1995 - 1997	Chairman of the Vice President's Faculty Research Committee
July 1994 - June 1995	Chairman of the Dean's Scientific Advisory Committee
September 1993 – April 1994	Acting Chairman, Department of Medicine
1990-1997	Director, Clinical Research Center
1989-1997	Vice-Chairman of Research, Department of Medicine
1988-1990	Interim Director, Clinical Research Center
November 1986 – April 1987	Acting Chairman, Department of Medicine
1975 – present	Professor of Medicine, University of New Mexico School of Medicine Chief, Division of Endocrinology and Metabolism Professor of Mathematics and Statistics

1970-1975	Associate Professor of Medicine, University of New Mexico School of Medicine
1968-1970	Assistant Professor of Medicine, University of New Mexico School of Medicine.

POST GRADUATE TRAINING:

Internship: 1961-1962	Straight Medical - Barnes Hospital, Washington University, St. Louis, Missouri
Research Associate: 1962-1965	National Heart Institute, NIH, Laboratory of Metabolism under supervision of Dr. Daniel Steinberg, Bethesda, MD (Public Health Service) Lt. Comdr. (fulfilling military obligation.)
Medical Resident: 1965-1966	Barnes Hospital, Washington University, St. Louis, Missouri
Fellowship: 1966-1968	Instructor and Trainee (NIAMD) in Medicine (Metabolism). Washington University, St. Louis, Missouri
Special Fellowship Grant: 1967	National Institute of Arthritis and Metabolic Disease
Research and Development Grant: 1967	American Diabetes Foundation
Research Career Development Award: 1970-1975	Lipid-Carbohydrate Metabolism KO4 HE 35843

SPONSORED RESEARCH

Eli Lilly Research Assistant:	"A physical chemical study of cholesterol- $\beta$ -sitosterol mixed crystal formation"
National Science Foundation Grant: 1958	"Intracellular and extracellular protein formation in streptococcus faecalis"
National Heart Institute Research Grant: 1968-1970, 1971-1973, 1975-1978, 1978- 1983	"Lipoprotein-Carbohydrate Metabolism"
Research Grant: The KROC Foundation 1972-1973, 1973-1974, 1974- 1975, 1975-1976, 1976-1977, 1977-1978, 1978-1980, 1980-1981, 1981-1982	"Glucose Homeostasis in Normal 1971-1972, man, Obesity, and Diabetes"
Research Grant: The KROC Foundation 1977-1978, 1978-1979, 1979-1980	"Programmable Insulin Delivery System"

1980-1981, 1981-1982, 1982-1983,  
1983-1984

National Institute of Arthritis,  
Metabolism and Digestive Diseases  
1979-1981, 1981-1985

"Development of an Artificial  
Beta Cell"

National Institute of Child Health and  
Development - Co-Principal Investigator  
1978-1985

"Physiologic and Developmental  
Mechanisms in Diabetes"

UNM/Shiley Agreement - 1983-1986

"Artificial Drug Delivery

NIH DHHS Co-P.I.  
1986-1993

"Diabetes Control and  
Complication Trial

The Flinn Foundation Grant  
1987-1990

"<sup>13</sup>C Magnetic-Resonance  
Spectroscopic Investigation of the  
Aldose-Reductase Pathway in-vivo in Diabetic  
Man"

Shiley-Infusaid, Inc.  
1987, -1988

"Intraperitoneal Insulin  
Delivery in Diabetic Dog"

NIH-NINCDS-87-03 Contract  
1988-92

"Magnetic Resonance for the  
Early Detection of Distal Symmetrical  
Peripheral Diabetic Neuropathy"

Sandia National Laboratories  
1989-Present

Biomedical engineering research program on  
Glucose Sensor and Fetal Monitor

1991

Biomedical engineering training program with Ries  
Robinson, M.D. as the first Engineer/M.D. Post Doc  
to participate

8/12/94 - 12/31/94

Noninvasive Finger Sampling Investigation

Wyeth-Ayerst Research  
1990-1992

Double blind, placebo controlled,  
randomized study of the safety and efficacy of  
Tolrestat in the treatment of elevated sural nerve  
water in diabetic patients

Johnson & Johnson/Lifescan  
1992-1995

Noninvasive Glucose Monitoring with  
Infrared Spectroscopy in Man

Federal Technology Reinvestment Project (TRP)  
1994 - 1996

Noninvasive Arterial Blood Gas  
Measurement

National Institutes of Health 09/01/99 – 08/31/02

Training Preceptors in Human Research Ethics:  
Augmentation

PROFESSIONAL SOCIETIES :

Association of American Physicians, 1983  
Western Association of Physicians, 1978

American Society of Clinical Investigation, 1976  
Western Society for Clinical Research, 1974  
American Federation of Clinical Research  
Fellow, American College of Physicians  
American Diabetes Association  
The Endocrine Society  
Society for Experimental Biology and Medicine  
Atherosclerosis, Council of American Heart Association  
Western Society of Clinical Investigation

PROFESSIONAL ACTIVITIES:

Invited Lecturer 1998 AOA Dinner UNM School of Medicine:  
"The Search for the Glucose Sensor" May 19, 1998.

Recipient of the 1995 Katali Award for Outstanding Clinical Teacher

Member of UNM Search Committee for President of UNM, 1997-1998

Board Member: Research Program Oversight Committee, Lovelace Respiratory Institute, 1997-

Member of Wellcome Trust Committee for Clinical Research Facilities Initiatives  
Site Visit in the United Kingdom, November, 1997

Board Member: Science and Technology Corporation at UNM 1997-

Member NIH General Clinical Research Center Study Section - 1981-1986, 1994 - 1997

Chairman, UNM Search of Vice President for Health Sciences, 1994

Member of Board of Directors of the Biomedical Research Institute of New Mexico , December, 1992

Member of National VA Merit Review Board for Endocrinology until June 30, 1992

Member of Albuquerque VA Medical Center Research Committee

Recipient of the 1989 Ralph C. Williams Third Annual Research Award for Distinguished Research Contributions  
in the Department of Medicine-October 1989.

Invited Lecturer - Thirty-Third Annual Western Association of Physicians Meeting: "The Nerve Hydration  
Hypothesis: Aldose Reductase Sensitive Participant in Diabetic Neuropathy"  
February 16, 1988.

Recipient of the 1987-88 Excellence in Teaching Award  
University of New Mexico School of Medicine

Recipient of the 1986 Distinguished Alumni Award University of Chicago Medical School

Recipient of the 1981 University of New Mexico Regents Meritorious Service Medal.

President, Western Society for Clinical Research, 1979-1980

Recipient of the 1979 Annual Research Lecturer of the University of New Mexico Faculty. "Problems in Human  
Biology: The Necessity for Collaborative Research"

Organizing Chairman, International Symposium, INSULIN IMPLANTATION DEVICES SYMPOSIUM,  
Sponsored by the KROC Foundation, December 3-7, 1979, Santa Ynez Valley, Ca.

Organizing Chairman, International Symposium, ADVANCES IN GLUCAGON RESEARCH, Sponsored by The  
KROC Foundation, October 13-16, 1974, Santa Ynez Valley, CA.

PATENT AWARDED:

U.S. Patent Application (SN 07/369,217). *Method of Apparatus for Determining the Similarity of a Biological Analyte From a Model Constructed From Known Biological Fluids.* Awardees: R. Philip Eaton, M.D., M. Ries Robinson, UNM School of Medicine, Kenneth J. Ward, David M. Haaland, Sandia National Laboratories, August 1990.

OFFICES SERVED:

University of New Mexico:

1969-1972	Research Policy Committee
1969-	Department of Medicine Executive Committee
1972-	Research Allocations Committee
1974-1975	Budget Advisory Committee
1974-1977	PSRO Executive Committee
1976	Medical Services Plan Committee
1976-	Clinical Research Executive Committee
1976	Ad Hoc Committee - Clinical Nutrition Program
1976-	New Mexico Medical Foundation Executive Committee
1977-1978	Interface Committee
1977-1979	Research Building Committee
1977-	Student Research Committee
1978	Interdepartmental Nutrition Committee
1978-1979	Advisory Committee for Biomedical Communications
1979	Accountability Audit Committee
1980	Ad Hoc Oncology Search Committee
1983-84	Master's Thesis Committee - Judith Brown
1983-84	Ph.D. Dissertation Supervisory Committee - Robin Meize-Grochowski
1985-86	President's Science & Technology Advisory Committee
1994	Chair of Search Committee for Vice President of Health Sciences
1995	Chair of Dean's Scientific Advisory Committee
1995	Chair of Research Advisory Committee to the Vice President of Health Sciences

American Diabetes Association:

1971-1974	Committee on Food and Nutrition
1978-1980	Committee on Research
1977	New Mexico Affiliate, President

American Heart Association:

1975-1978	Southwest Regional Research Review and Advisory Committee
1979-1980	New Mexico Affiliate, Committee on Research
1979-1981	New Mexico Affiliate, Board of Directors
1979-1981	New Mexico Affiliate, Program Advisory Committee
1980-1983	American Heart Association Nutrition Committee NIH
1980-1983	General Clinical Research Committee

EDITORIAL ASSIGNMENTS:

Journal of Clinical Endocrinology Metabolism  
Diabetes  
Metabolism  
Endocrinology  
Journal of Clinical Investigation  
Diabetologia  
Diabetes and Metabolism  
Diabetes Care  
American Journal of Medicine  
American Physiological Society  
Journal of Laboratory and Clinical Medicine  
Hormone and Metabolic Research  
New England Journal of Medicine  
Clinical Diabetes

PERSONAL PUBLICATIONS - R. PHILIP EATON, M. D.

1961:

1. Eaton RP and Steinberg D. Effects of medium fatty acid concentration, epinephrine and glucose on palmitate-1-c oxidation and incorporation into neutral lipids by skeletal muscle in-vitro. *Journal of Lipid Research*. 2:376-383, 1961.
2. Eaton RP. In-vitro inhibition of the fat-mobilizing action of norepinephrine. *Proceedings of the Society for Experimental Biology & Medicine*. 114:599-600, 1963.

1964:

3. Eaton RP. Kinetic analysis of biological compartments illustrated by investigation of fatty acid metabolism using computer data processing. *Proceedings of the Symposium on Respiration Pattern Analysis in Intermediary Metabolism Study*. (Applied Physics Corp. and Baird-Atomic, Inc.) pp. 11-32, 1964.

1967:

4. Eaton RP, Steinberg D, and Thompson RH. Relationship between free fatty acid turnover and total body oxygen consumption in the euthyroid and hyperthyroid states. *Journal of Clinical Investigation*. 44:247-260, 1967.

1969:

5. Eaton RP, Berman M and Steinberg D. Kinetic studies on plasma free fatty acid and triglyceride metabolism in man. *Journal of Clinical Investigation*. 48:1560-1579, 1969.
6. Eaton RP and Kipnis DM. Effect of glucose feeding on lipoprotein synthesis in the rat. *American Journal of Physiology*. 217:1153, 1969.
7. Eaton RP and Kipnis DM. Effects of high-carbohydrate diets on lipid and carbohydrate metabolism in the rat. *American Journal of Physiology*. 217:1160, 1969.
8. Eaton RP and Kipnis DM. Radioimmunoassay of beta lipoprotein-protein of rat serum. *Journal of Clinical Investigation*. 48:1387-1396, 1969.

1970:

9. Heffron W and Eaton RP. Thyrotoxicosis presenting as choreoathetosis. *Annals of Internal Medicine*. 73:425-428, 1970.

1971:

10. Eaton, RP. Synthesis of plasma triglycerides in endogenous hyper-triglyceridemia. *Journal of Lipid Research*. 12:491-498, 1971.

1972:

11. Eaton RP and Kipnis DM. Incorporation of Se<sup>75</sup>-selenomethionine into a protein component of plasma very-low-density lipoprotein in man. *Diabetes*. 21:744-753, 1971.
12. Eaton RP, Conway M and Buckman M. Role of alpha adrenergic blockade on alanine-induced hyperglucagonemia. *Metabolism*. 21:371, 1972.
13. Eaton RP. Cobalt chloride induced hyperlipemia in the rat. Effects on intermediary metabolism. *American Journal of Physiology*. 222:1550-1557, 1972.
14. McCroskey RC and Eaton RP. Hyperparathyroidism: Parathyroid hormone immunoassay in clinical diagnosis. *Rocky Mountain Medical Journal*.. 69:41-45, 1972.

1973:

15. Schade DS and Eaton RP. Metabolic and clinical significance of ketosis. *Special Topics in Endocrinology & Metabolism*. 4:1-27, 1982.
16. Eaton RP. Effect on clofibrate on arginine-induced insulin and glucagon secretion. *Metabolism: Clinical & Experimental*. 22:763-767, 1973.
17. Calodney L, Eaton RP, Black W, and Cohn F. Exacerbation of Cushing's Syndrome during pregnancy: Report of a case. *Journal of Clinical Endocrinology & Metabolism* 36:81-86, 1973.
18. Eaton RP and Nye WHR. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia. *Journal of Laboratory and Clinical Medicine*. 81:682-695, 1973.
19. Eaton RP. The hypolipemic action of glucagon in experimental endogenous lipidemia in the rat. *Journal of Lipid Research* 14:312-318, 1973.
20. Eaton RP. Glucagon secretion and activity in the cobalt-chloride treated rat. *American Journal of Physiology*. 225:67-73, 1973.
21. Buckman M, Conway M, Seibel JA, and Eaton RP. Effect of fasting upon alanine-stimulated insulin and glucagon secretion. *Metabolism*. 22:1253-1262, 1973.
22. Eaton RP and Schade DS. Hypothesis: glucagon resistance: An hormonal basis for endogenous hyperlipemia. *Lancet*. May 5, pp. 973-974, 1973.

1974:

23. Eaton RP and Schade DS. The effect of clofibrate on arginine stimulated glucagon and insulin secretion in man. *Metabolism*. 23:445-454, 1974.
24. Eaton RP, Schade DS, and Conway MJ. Decreased glucagon activity: A mechanism for genetic and acquired endogenous hyperlipemia. *Lancet*. Dec. 28, p. 1545.
25. Conway MJ, Seibel JA, and Eaton RP. Thyrotoxicosis and periodic paralysis: improvement with beta blockade. *Annals of Internal Medicine*. 81:332-336, 1974.
26. Schade DS and Eaton RP. Role of insulin and glucagon in obesity. *Diabetes* 23:657-71, 1974.

27. Eaton RP, Kipnis DM, Karl I, and Eisenstein AB. Effects of glucose feeding on insulin and glucagon secretion and hepatic gluconeogenesis in the rat. *American Journal of Physiology*. 227:101-104, 1974.
28. Davis RL, Girard DL, and Eaton RP. Hormonal basis for the dumping syndrome. *Rocky Mountain Medical Journal*. 71:94-98, 1974.

1975:

29. Schade DS and Eaton RP. Modulation of fatty acid metabolism by glucagon in man. *Diabetes*. 24:502-509, 1975.
30. Schade DS and Eaton RP. Modulation of fatty acid metabolism by glucagon in man II: Effects in insulin deficient diabetics. *Diabetes*. 24:510-515, 1975.
31. Schade DS and Eaton RP. Insulin secretion by perfused islets from the obese Zucker rat. *Proceedings of the Society for Experimental Biology & Medicine*. 149:311-314, 1975.
32. Schade DS and Eaton RP. Altered tissue response to glucagon in obesity. *Journal of Clinical Endocrinology & Metabolism*. 40:732-735, 1975.
33. Eaton RP. Evolving role of glucagon in human diabetes mellitus. *Diabetes*. 24:523-524, 1975.
34. Shuck LW, Eaton RP, Shuck JM. Glucagon, insulin, and glucose relationships in severely burned patients. *Surgical Forum XXVI*. pp. 39-42, 1975.
35. Beck P, Eaton RP, Arnett DM, and Alsever RN. Effect of contraceptive steroids on arginine-stimulated glucagon and insulin secretion in women: I. Lipid physiology. *Metabolism*. 24:1055-1065, 1975.
36. Schade DS and Eaton RP. Glucagon regulation of plasma ketone body concentration in human diabetes. *Journal of Clinical Investigation*. 56:1340-1344, 1975.
37. Schade DS and Eaton RP. Modulation of fatty acid metabolism by glucagon in man III. Role of pharmacological limitation of FFA availability. *Diabetes*. 24:1020-1026, 1975.
38. Schade DS and Eaton RP. The contribution of endogenous insulin secretion to the ketogenic response to glucagon in man. *Diabetologia* 11:555-559, 1975.
39. Wilson DE, Flowers CM, Hershgold EJ, and Eaton RP. Multiple myeloma, cryoglobulinemia and xanthomatosis. *American Journal of Medicine* 59:721-730, 1975.

1976:

40. Beck P, Arnett DM, Alsever RN, and Eaton RP. Effect of contraceptive steroids on arginine-stimulated glucagon and insulin secretion in women: II. Carbohydrate and lipid physiology in insulin-dependent diabetics. *Metabolism*. 25:23-31, 1976.
41. Eaton RP, Schade DS, and Oase R. Altered insulin and glucagon secretion in treated genetic hyperlipemia: A mechanism of therapy. *Metabolism*. 25:245-249, 1976.
42. Eaton RP, Conway M, and Schade DS. Endogenous glucagon regulation in genetically hyperlipemic obese rats. *American Journal of Physiology*. 230:1336-1341, 1976.
43. Eaton RP. Incorporation of Se<sup>75</sup>-selenomethionine into human apoproteins. I. Characterization of specificity in very-low-density and low-density lipoproteins. *Diabetes* 25:32-36, 1976.

44. Eaton RP, Crespin S and Kipnis DM. Incorporation of Se<sup>75</sup>-selenomethionine into human apoproteins. II. Characterization of metabolism of very-low-density and low-density lipoproteins in vivo and in-vitro. *Diabetes*. 25:44-50, 1976.
45. Eaton RP, Crespin S, and Kipnis DM. Incorporation of Se<sup>75</sup>-selenomethionine into human apoproteins. III. Kinetic behavior of isotopically labeled plasma apoprotein in man. *Diabetes*. 25:679-90, 1976.
46. Schade DS and Eaton RP. Modulation of fatty acid metabolism by glucagon in man: IV. Effect of physiologic hormone infusion in normal man. *Diabetes*. 25:978-983, 1976.
47. Eaton RP. Glucagon and lipoproteins. *Metabolism*. 25:1415-17, 1976.

1977:

48. Eaton RP and Schade DS. Modulation of the catabolic activity of glucagon by endogenous insulin secretion in obese man. *Acta Diabetologica Latina*. XIV: 62-72, 1977.
49. Schade DS and Eaton RP. Dose response to insulin in man: Differential effects on glucose and ketone body regulation. *Journal of Clinical Endocrinology & Metabolism*. 44:1038-1053, 1977.
50. Schade DS and Eaton RP. The effect of short term physiological elevations of plasma glucagon concentration on plasma triglyceride concentration in normal and diabetic man. *Hormone and Metabolic Research*. 9:253-257, 1977.
51. Schade DS, Eaton RP, and Standefer J. Glucocorticoid regulation of plasma ketone body concentration in insulin deficient man. *Journal of Clinical Endocrinology & Metabolism*. 44:1069-1079, 1977.
52. Schade DS and Eaton RP. The controversy concerning counter regulatory hormone secretion: An hypothesis for the prevention of diabetic ketoacidosis. *Diabetes*. 26:596-601, 1977.
53. Eaton RP, Schade DS and Lueker RL. Clofibrate-induced changes in glucagon and insulin secretion in patients with angiographically documented coronary artery disease. *American Journal of Clinical Nutrition*. 30:2068-2077, 1977.
54. Beck P, Zimmerman DE and Eaton RP. Effect of contraceptive steroids on arginine-stimulated glucagon and insulin secretion in women. III. Medroxyprogesterone Acetate. *Metabolism*. 26:1193-1197, 1977.
55. Schade DS and Eaton RP. The regulation of plasma ketone body concentration by counter-regulatory hormones in man. I. Effects of norepinephrine in diabetic man. *Diabetes*. 26:989-996, 1977.
56. Eaton RP. Glucagon and lipoprotein regulation in man. (Ch) *Glucagon, Its Role in Physiology and Clinical Medicine*, Eds. Foa PO, Bajaj JS and Foa NL. Springer-Verlag, New York 1977, pp. 533-551.
57. Eaton, RP. The lipoprotein cascade: clinical implications of hyperlipemia. *Continuing Education for the Family Physician*. December, pp. 42-49, 1977.
58. Shuck JM, Eaton RP, Shuck LW, Wachtel TL and Schade DS. Dynamics of insulin and glucagon secretions in severely burned patients. *Journal of Trauma*. 17:706-713, 1977.
59. Omdahl JL, Jelinek G, and Eaton RP. Kinetic analysis of 25-hydroxy-vitamin D-3 metabolism in strontium induced rickets in the chick. *Journal of Clinical Investigation*. 60:1202-1210, 1977.

60. Schade DS, Kaufman E, and Eaton RP. Diabetic ketoacidosis: Counterregulatory hormones versus insulin in therapeutic response. Report of a Case. *Rocky Mountain Medical Journal*. 74:312-315, 1977.

1978:

61. Eaton, RP and Schade DS. The modulation and implication of glucagon and (Ch) other hormones in diabetes and obesity. *Advances in Modern Nutrition*\_(Ed.) Katzen HM and Mahler RJ. Hemisphere Publishing Corporation, Vol. II, 1978.
62. Simonelli C. and Eaton RP. Cardiovascular and metabolic effects of exercise: The strong case for conditioning. *Postgraduate Medicine*. 63:71-77, 1978.
63. Conway M, Friedrich J, Schade DS, Buckman M, and Eaton RP. The effect of altered autonomic tone on alanine induced insulin secretion. *Hormone and Metabolic Research*. 10:290-294, 1978.
64. Wachtel TL, Shuck JM, Eaton RP, Schade DS, Shuck LW. Glucagon, insulin, and glucose relationships in a porcine experimental burn model. *Journal of Surgical Research*. 24:70-78, 1978.
65. Norris B, Schade DS, and Eaton RP. Effects of altered free fatty acid mobilization on the metabolic response to exercise. *Journal of Clinical Endocrinology & Metabolism* 46:254-259, 1978.
66. Schade DS, Eaton RP, George S, Conway M, Kaminsky N, and Sivinski J. The metabolic effects of clofibrate in insulin dependent, ketosis prone diabetic man. *Metabolism*. 27:461-468, 1978.
67. Simonelli C and Eaton RP. Reduced triglyceride secretion: A metabolic consequence of chronic exercise. *American Journal of Physiology*. 243:E 221-227, 1978.
68. Eaton, R. P., Wm. Spencer, D. S. Schade, B. D. Shafer, and W. Corbett. Diabetic glucose control: Matching plasma insulin concentration to dietary and stress hyperglycemia. *Diabetes Care*. 1:40-45, 1978.
69. Eaton RP. High density lipoprotein: Key to anti-atherogenesis. *Journal of Chronic Diseases*. 33:151-155, 1978.
70. Simonelli C and Eaton RP. Effect of clofibrate on in-vivo triglyceride production and clearance in genetically hyperlipidemic rats. *Atherosclerosis*. 29:269-275, 1978.
71. Wachtel TW, Shuck JM, Schade DS, Eaton RP, and Shuck LW. Hyper-glucagonemia and hepatic ketogenesis in burned swine. *Journal of Trauma*. 18:248-253, 1978.
72. Schade DS, Eaton RP, and Standefer J. The modulation of basal ketone body concentration by cortisol in diabetic man. *Journal of Clinical Endocrinology & Metabolism*. 47:519-528, 1978.
73. Schade DS, Eaton RP, and Peake GT. The regulation of plasma ketone body concentration by counter-regulatory hormones in man. II. Effects of growth hormone in diabetic man. *Diabetes*. 27:916-24, 1978.
74. Schade DS, Burke G, Eaton RP, and DeMoss J. Semi-automated microscale extraction apparatus for assay of free fatty acids in plasma. *Clinical Chemistry*. 24:1614-15, 1978.
75. Schade DS and Eaton RP. The metabolic response to norepinephrine in normal versus diabetic man. *Diabetologia*. 15:433-439, 1978.
76. Hooper PL and Eaton RP. Exercise, High Density Lipoprotein and Coronary (Ch) Artery Disease. (Eds.) Otto Appenzeller and Ruth Atkinson (Publ.) Thomas Karger, Basel, Switzerland. *Medicine and Sports*. 12:72-84, 1978.

77. Eaton RP. Metabolic and hormonal consequences of chronic exercise. *Practical Cardiology*. Sept. pp. 155-157, 1978.

1979:

78. Herndon CM, Schade DS, and Eaton RP. The differential effect of insulin in-vivo on the peripheral utilization of glucose and ketone bodies in the rat. *Hormone and Metabolic Research* 11:261-322, 1979.
79. Isaac RM, Hayek A, Standefer JC, and Eaton RP. Reverse Tri-iodothyronine to Tri-iodothyronine (rT<sub>3</sub>/T<sub>3</sub>) ratio and gestational age. *Journal of Pediatrics*. 94(3): 477-79, 1979.
80. Schade DS and Eaton RP. The regulation of plasma ketone body concentration by counter-regulatory hormone in man III. Effects of norepinephrine in normal man. *Diabetes*. 28:5-10, 1979.
81. Schade DS and Eaton RP. The differential diagnosis and therapy of the hyperketonemic state. *JAMA*. 24:2064-2065, 1979.
82. Riley MS, Schade DS, and Eaton RP. Preliminary report. Effects of insulin infusion on plasma phosphate in diabetic patients. *Metabolism*. 28:191-194, 1979.
83. Schade DS, Eaton RP, Spencer W, Goldman R and Corbett WR. Preliminary report. The peritoneal absorption of insulin in diabetic man: A potential site for a mechanical insulin delivery system. *Metabolism*. 28:195-197, 1979.
84. Eaton RP. Lipids and diabetes: the case for treatment of macrovascular disease. *Diabetes Care*. 2:46-50, 1979.
85. Schade DS and Eaton RP. Pathogenesis of diabetic ketoacidosis: a reappraisal. *Diabetes Care*. 2:296-306, 1979.
86. Schade DS, Eaton RP, and Woodside W. The role of glucagon in the regulation of plasma lipids. *Metabolism*. 28:874-886, 1979.
87. Schade DS and Eaton RP. The prevention of diabetic ketoacidosis. *JAMA*. 242:2455-2458, 1979.
88. Schade DS, Eaton RP, and Friedman N. The intravenous, intraperitoneal, and subcutaneous routes of insulin delivery in diabetic man. *Diabetes*. 28:1069-1072, 1979.
89. Omdahl JL, Allen RC, and Eaton RP. Computer modeling of Vitamin D (Ch) Metabolism. *Vitamin D, Basic Research and its Clinical Application*, (Eds) Walter de Gruyter and Co., Berlin, New York, pp. 515-521, 1979.
90. Allen RC, Eaton RP, Erickson KM, and Schade DS. Kinetic analysis of insulin behavior by interactive simulation. *Proceedings of the Seventh New England Bioengineering Conference*. (Ed) L. E. Ostrander, pp. 65-68, 1979.

1980:

91. Schade DS, Eaton RP, Mitchell W, and Ortega T. Glucose and insulin response to high carbohydrate meals in normal and maturity-onset diabetic man. *Diabetes Care*. 3:242-44, 1980.
92. Eaton RP and Schade DS. Stress hormones and metabolic decompensation in man. *Excerpta Medica*. (In press, 1982).

93. Schade DS and Eaton RP. The temporal relationship between endogenously secreted stress hormones and metabolic decompensation in diabetic man. *Journal of Clinical Endocrinology & Metabolism*. 50:131-136, 1980.
94. Schade DS, Eaton RP, and Spencer WJ. Normalization of plasma insulin profiles in diabetic man with programmed insulin delivery. *Diabetes Care*. 3:9-14, 1980.
95. Eaton RP and Schade DS. The effect of diazoxide-induced hormonal secretion on plasma triglyceride concentration in the rat. *Diabetologia*. 18:301-306, 1980.
96. Schade DS and Eaton RP. The peritoneum - a potential insulin delivery route for a mechanical pancreas. *Diabetes Care*. 3:229-234, 1980.
97. Eaton RP, Allen RC, Schade DS, and Standefer JC. "Normal" insulin secretion: The goal of artificial insulin delivery systems. *Diabetes Care*. 3:270-73, 1980.
98. Schade DS, Eaton RP, Friedman NM, and Spencer WJ. Prolonged peritoneal insulin infusion in diabetic man. *Diabetes Care*. 3:314-17, 1980.
99. Spencer WJ, Bair RE, Carlson GA, Love JT, Urenda RS, Eaton RP and Schade DS. Some engineering aspects of insulin delivery systems. *Diabetes Care*. 3:345-50, 1980.
100. Spencer WJ, Corbett W, Schade DS, Eaton RP and Shafer BD. Modified hospital pumps for pulsed insulin delivery. *Medical Progress through Technology*. 7:45-55, 1980.
101. Schade DS, Eaton RP, Friedman NM, and Spencer WJ. Intraperitoneal delivery of insulin by a portable micro -infusion pump. *Metabolism*. 29:699-702, 1980.
102. Engelken S and Eaton RP. Thyroid hormone induced dissociation between plasma triglyceride and cholesterol regulation in the rat. *Endocrinology*. 107:208-214, 1980.
103. Carlson GA, Love JT, Urenda RS, Bair RE, Spencer WJ, Shuck JM, Eaton RP, Schade DS, and Day PW. Development of an artificial beta cell suitable for animal implantation. *Proceedings of the American Society for Artificial Internal Organs, Inc*. 26:523-26, 1980.
104. Eaton RP, Allen RC, Schade DS, Erickson KM, and Standefer J. Prehepatic insulin production in man: Kinetic analysis utilizing peripheral connecting peptide behavior. *Journal of Clinical Endocrinology & Metabolism*. 51:520-528, 1980.
105. Schade DS, Eaton RP, Friedman NM, and Spencer WJ. Normalization of plasma insulin profiles with peritoneal insulin infusion in diabetic man. *Diabetologia* 19:35-39, 1980.
106. Schade DS and Eaton RP. The clinical use of oral hypoglycemic agents - interpretations of the UGDP study. *Practical Cardiology*. 6:181-91, 1980.
107. Schade DS, Eaton RP, and Peake GT. The ketotic effects of glucocorticoid and growth hormone in man. *Acta Diabetol. Lat*. XVII:161-169, 1980.
108. Carlson GA, Love JT, Urenda RS, Spencer WJ, and Eaton RP. A portable insulin infusion system with a rotary solenoid-driven peristaltic pump. *Medical Progress through Technology*. 8:49-56, 1980.
109. Schade DS and Eaton RP. The mechanism of improvement in glucose tolerance (Ch) with clofibrate. (Eds) Fumagalli R, Kritchevsky D, and Paoletti R. *Drugs Affecting Lipid Metabolism*. Amsterdam. Elsevier/North-Holland Biomedical Press, pp. 311-19, 1980.

110. Eaton RP. Insulin delivery devices. Proceedings of the KROC Foundation International Conference. *Diabetes Care* 3:253-254, 1980.

1981:

111. Engelken SF and Eaton RP. The effects of altered thyroid status on lipid metabolism in the genetic hyperlipemic Zucker rat. *Atherosclerosis*. 38:177-188, 1981.
112. Schade DS, Eaton RP, and Spencer WJ. Implantation of an artificial pancreas - current perspectives. *JAMA*. 245:709-10, 1981.
113. Schade DS, Eaton RP, Friedman NM and Spencer WJ. Five-day programmed intraperitoneal insulin delivery in insulin-dependent diabetic man. *Journal of Clinical Endocrinology & Metabolism*. 52:1165-1170, 1981.
114. Schade DS, Eaton RP, Davis T, Akiya F, Phinney E, Kubica R, Vaughn EA and Day PW. The kinetics of peritoneal insulin absorption. *Metabolism*. 30:149-155, 1981.
115. Eaton RP, Galagan R, Kaufman E, Allen RC. Receptor depletion in diabetes mellitus and correction with therapy. *Diabetes Care*. 2:299-304, 1981.
116. Schade DS, Eaton RP, Carlson GA, Bair RE, Gaona JI Jr., Love JT, Urenda RS and Spencer WJ. Future therapy of the insulin-dependent diabetic - the implantable insulin delivery system. *Diabetes Care*. 4:319-324, 1981.
117. Schade DS, Eaton RP, Mitchell WJ and Friedman NM. Intravenous home blood glucose monitoring. *Diabetes Care*. 4:420-423, 1981.
118. Schade DS and Eaton RP. Insulin Delivery - Today's Systems, Tomorrow's Prospects. *Drug Therapy*. 11:47-55, 1981.
119. Schade DS and Eaton RP. The ketotic ratio (KB/NEFA) in man. *Clinical & Experimental Pharmacology & Physiology*. 8:303-313, 1981.
120. Schade DS, Eaton RP and Wm. J. Spencer. The Advantages of the Peritoneal (Ch) Route of Insulin Delivery. *New Approaches to Insulin therapy*. (Eds) Irsigler, Karl, D. N. Kunz, D. R. Owens, H. Regal, MTP Press, Lancaster, England, pp. 31-39, 1981.
121. Hooper PL and Eaton RP. Lipid and Sports: Protection from Coronary (Ch) Artery Disease. *Sports Medicine*. Appenzeller, O., Ed., Baltimore, Urban and Schwarzenberg, Inc., Chapter 12, pp. 189-201, 1981.
122. Eaton RP, Allen RC, Koopmans LH, Ellis H, Abrams J, and Schade DS. (Ch) Overview of lipoprotein metabolism: Perspectives in a free-living Southwest population in Bernalillo County, New Mexico. *Human Nutrition Clinical and Biochemical Aspects*, Ed. Garry, P. J., Amer. Assn. for Clin. Chem. Washington, DC, 1981: 109-120.

1982:

123. Allen RC, Eaton RP, Erickson KM. KABIS: Kinetic analysis by interactive (Ch) simulation. Lipoprotein Kinetics and Modeling. (Eds.) M. Berman, S. M. Grundy, B. V. Howard. Academic Press. pp. 417-425, 1982.
124. Eaton RP, Allen RC, and Schade DS. Beta-apolipoprotein secretion in man: (Ch) Investigation by analysis of Se<sup>75</sup>-aminoacid incorporation into apoprotein. Lipoprotein Kinetics and Modeling. (Eds.) M. Berman, S. M. Grundy, B. V. Howard. Academic Press. pp. 77-97, 1982.

125. Wilson JN, Wilson SP, and Eaton RP. Influence of genetic hyperlipemia in the zucker rat upon the lipemic response to graded estradiol exposure. *Atherosclerosis* 41:99-114, 1982.
  126. Schade DS, Eaton RP, McDowell B, Kubica R, Vaughn E, Carlson G, and Spencer W. Total implantation of an insulin delivery device. *Hormone and Metabolic Research Supplement*. 12:267-270, 1982.
  127. Schade DS, Eaton RP, DeLongo J, Saland LC, Ladman AJ and Carlson GA. Electron microscopy of insulin precipitates. *Diabetes Care* 5:25-30, 1982.
  128. Schade DS and Eaton RP. Bactericidal properties of commercial U.S.P. formulated insulin. *Diabetes* 31:36-9, 1982.
  129. Eaton, RP. Portable insulin infusion pumps: What is their role in therapy. *Drugs* 23:245-249, 1982.
  130. Schade DS and Eaton RP. Intraperitoneal insulin delivery. *Artificial Systems for Insulin Delivery*. P. Brunetti, (Ed). Raven Press New York, pp. 161-166, 1983.
  131. Schade DS, Eaton RP, Edwards WS, Doberneck RC, Spencer WJ, Carlson GA, Bair RE, Love JT, Urenda RS, and Gaona JI, Jr. A remotely programmable insulin delivery system. Successful short-term implantation of a remotely programmable insulin delivery system in man. *JAMA*. 247:1848-53, 1982.
  132. Eaton RP, Allen RC, and Schade DS. Metabolic heterogeneity of ldl-apob production in familial hyper-cholesterolemia: an analytical model solution of tracer data. *Journal of Lipid Research*. 23:738-746, 1982.
  133. Eaton RP and Schade DS. Hormonal antagonists of insulin. Diabetes (Ch) Mellitus and Obesity, (Eds.) Williams and Wilkins, Baltimore pp. 27-34, 1982.
  134. Schade DS, Eaton RP, Warhol RM, Gregory JA, and Doberneck RC. Subcutaneous peritoneal access device for type I diabetic patients non-responsive to subcutaneous insulin. *Diabetes* 31:470-473, 1982.
  135. Carlson GA, Bair RE, Gaona JI Jr., Schildknecht HE, Love JT, Urenda RS, Spencer WJ, Eaton RP, and Schade DS. An implantable, remotely- programmable insulin infusion system. *Medical Progress through Technology* 9:17-25, 1982.
  136. Eaton, R. P. and D. S. Schade. Normal human insulin secretion: the goal of (Ch) management of the diabetic patient. *Diabetes Management in the '80's The Role of home blood glucose monitoring and new insulin delivery systems*, (Ed.) C. M. Peterson. pp 82-88, 1982.
  137. Schade DS and Eaton RP. A clinician's guide to subcutaneous insulin (Ch) infusion based on the kinetics of insulin absorption from subcutaneous tissue. *Diabetes Management in the '80's: The Role of Home Blood glucose monitoring and new insulin delivery systems*. (Ed.) C. M. Peterson. pp. 110-115, 1982.
  138. Schade DS. Eaton RP. Metabolic and clinical significance of ketosis. *Special Topics in Endocrinology & Metabolism*. 4:1-27, 1982.
- 1983:
139. Standefer JC and Eaton RP. Evaluation of a colorimetric method for determination of glycosylated hemoglobin. *Clinical Chemistry*. 29:135-140, 1983.
  140. Schade DS and Eaton RP. Hormonal interrelationships. Diabetes Mellitus.

(Ch) Theory and Practice, Third Edition. (Eds.) Max Ellenberg and Harold Rifkin. Chap. 12 pp. 255-266, 1983.

141. Eaton RP, Allen RC and Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. *Journal of Clinical Endocrinology & Metabolism*. 56:1294-1300, 1983.
142. Eaton RP. Portable insulin infusion pumps: what is their role in therapy. *New Ethicals*. January, pp. 7-11, 1983.
143. Allen RC, Eaton RP, and Hunt WC. Kinetic analysis by interactive simulation - kabis. Technical report No. 373, University of New Mexico, Department of Mathematics and Statistics, Albuquerque, New Mexico, 1983.
144. Eaton RP, Allen RC, and Schade DS. Overproduction of a kinetic subclass of vldl-apob, and direct catabolism of vldl-apob in human endogenous hypertriglyceridemia: an analytical model solution of tracer data. *Journal of Lipid Research*. 24:1291-1303, 1983.
145. Schade DS and Eaton RP. Diabetic ketoacidosis - pathogenesis, prevention (Ch) and therapy in clinics. *Endocrinology and Metabolism* 12:321-338, 1983.
146. Eaton RP. Glucagon and hyperlipoproteinemias. Glucagon II. (Ch) (Ed) P. J. Lefebvre. Chap. 21 pp. 467-476, 1983
147. Eaton RP, Schade DS, and Pitcher L. Catheter encapsulation during prolonged (Ch) intraperitoneal insulin infusion in a patient implanted with a remotely controlled insulin delivery system. Proceedings of the International Study Group on Diabetes Treatment with Implantable Insulin Delivery Devices. 14, pp. 126-131, 1983.
148. Schade DS and Eaton RP. Intraperitoneal insulin in brittle diabetes. Brittle (Ch) Diabetes. Pickup, J. C., Ed., Oxford, Blackwell Scientific Publication, Ltd., Chap. 21, pp. 275-288, 1983.

1984:

149. Eaton RP, Friedman N, Allen RC and Schade DS. Insulin removal in man: in vivo evidence for a receptor mediated process. *Journal of Clinical Endocrinology & Metabolism*. 58:555-559, 1984.
150. Schade DS and Eaton RP. Remotely controlled, implantable versus manually controlled, external insulin pump. *Western Journal of Medicine*. 140(6): 948-951, 1984.
151. Wilson JN, Wilson SP and Eaton RP. Dietary fiber and lipoprotein metabolism in the genetically obese (fafa) Zucker. *Arteriosclerosis*. 4:147-154, 1984.
152. Eaton RP, McConnell T, Hnath JG, Black W. Coronary myointimal hyperplasia in fresh-water lake Michigan salmon (genus *Oncorhynchus*): evidence for lipoprotein related atherosclerosis. *American Journal of Pathology*. 116:311-318, 1984.
153. Reynolds JH, Kaminsky NI, Schade DS and Eaton RP. Use of a computerized glucose clamp to diagnose an insulinoma. *Annals of Internal Medicine*. 101:649-650, 1984.

1985:

154. Schade DS, Drumm DA, Eaton RP, and Sterling WA. Factitious brittle diabetes mellitus. *American Journal of Medicine*. 78:777-784, 1985.
155. Eaton RP. Hyperlipoproteinemia. Nutrition and Metabolism in Patient Care. (Ch) (Eds.) Kinney, J.M., K. N. Jeejeebhoy, G. L. Hill, and O. E. Owen. W. B. Saunders Company, Philadelphia, PA, Chap. 25 pp. 465-476, 1988.

156. Schade DS, Eaton RP, Drumm DA, and Duckworth WC. A clinical algorithm to determine the etiology of brittle diabetes. *Diabetes Care*. 8:5-11, 1985.
157. Schade DS, Drumm DA, Duckworth WA, and Eaton RP. The etiology of incapacitating brittle diabetes. *Diabetes Care*. 8:12-20, 1985.
158. Eaton RP, Allen RC, and Schade DS. Preliminary studies of the influence of intraperitoneal insulin at physiologic dosage upon glucose production and utilization in diabetic man. Diabetes Treatment with Implantable Insulin - Munich "Continuous Insulin Infusion Therapy - Experience from a Decade". p. 126-31, 1985.
159. Schade DS and Eaton RP. Implanted devices and the artificial pancreas. (Ch) *The Diabetes Annual/I* (Eds.) K.G.M.M. Alberti and L. P. Krall. pp. 152-161, 1985.
160. Eaton RP and Sibbitt WL, Jr. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. *JAMA*. 253(10):1437-1440, 1985.
161. Eaton RP. Sorbinil and limited joint mobility in diabetes. *JAMA*. 254:1452-53, 1985. (Letter to Editor).
162. Schade DS and Eaton RP. Insulin delivery: how, when and where. *New England Journal of Medicine*. 312:1120-1121, 1985.
163. Eaton RP and Sibbitt WL, Jr. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. *JAMA, Southeast Asia*. 1:60-64, 1985.

1986:

164. Eaton RP. The collagen hydration hypothesis: a new paradigm for the secondary complications of diabetes mellitus. *Journal of Chronic Diseases*. 39(10):763-766, 1986.
165. Eaton RP. Aldose reductase inhibition and the diabetic syndrome of limited joint mobility: implications for altered collagen hydration. *Metabolism*. 35:(4) (Suppl. I) April pp. 119-121 1986.
166. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, and Creutzfeldt W. Incretion effects of increasing glucose loads in man calculated from venous insulin and c-peptide responses. *Journal of Clinical Endocrinology & Metabolism*. 63:492-498, 1986.

1987:

167. Griffey RH, Eaton RP, Gasparovic C, Sibbitt WL, Jr. Galactose neuropathy: structural changes evaluated by nuclear magnetic resonance spectroscopy. *Diabetes*. 36(6):776-78, 1987.
168. Argoud GM, Schade DS and Eaton RP. Underestimation of hepatic glucose production by radioactive and stable tracers. *American Journal of Physiology*. 252:E606-E615, 1987.
169. Argoud GM, Schade DS, and Eaton RP. Insulin suppresses its own secretion in-vivo. *Diabetes*. 36:959-62, 1987.

1988:

170. Griffey RH, Scavini M and Eaton RP. Characterization of the carbamino adducts of insulin. *Biochemical Pharmacology*. 37:1051-1056, 1988.
171. Vander Jagt DL, Stangebye LA, Hunsaker LA, Eaton RP and Sibbitt WL, Jr. Purification of aldose reductase from human placenta and stabilization of the inhibitor binding site. *Biochemical Pharmacology*. 37(6):1051-56, 1988.

172. Griffey RH, Eaton RP, Sibbitt RR, Sibbitt WL, Jr., and Bicknell JM. Diabetic neuropathy: structural analysis of nerve hydration by magnetic resonance spectroscopy. *JAMA*. 260:2872-78, 1988.

1989:

173. Argoud GM, Schade MS, Eaton RP, and Sterling WA. The C-peptide suppression test and recurrent insulinoma. *American Journal of Medicine*. 86:335-337, 1989.
174. Sibbitt W, Jr., Mills RG, Bigler C, Eaton RP, Griffey R, and Vander Jagt D. Glucose inhibition of human fibroblast proliferation and response to growth factors is prevented by inhibitors of aldose reductase. *Mechanisms of Aging and Development*. 47:265-279, 1989.
175. Zager PG, Eaton RP, Frey HJ, Scavini M, Jackson JE. Increased urinary prostaglandin excretion in galactose-fed rats. *Metabolism*. 38(7):603-605, 1989.
176. Griffey RH, Eaton RP, Sibbitt RR, Sibbitt WL, Jr., Bicknell JM. Diabetic Neuropathy: Structural analysis of nerve hydration by magnetic resonance spectroscopy. *JAMA, Southeast Asia*. 5(2):43-51, February 1989.

1990:

177. Ward KJ, Haaland DM, Robinson MR, Eaton RP. Quantitative infrared spectroscopy of glucose in blood using partial least-squares analyses. *Proceedings of S.P.I.E.* 1145:600-607, 1990.

1991:

178. Lowry S, Eaton RP, Standefer J, Nelson C. Unusual hyperthyroxinemia due to endogenous thyroxine antibodies. *Clinical Chemistry*. 37(9):1656-1657, November, 1991.

1992:

179. Ward KJ, Haaland DM, Robinson MR, Eaton RP. Post prandial blood glucose determination by quantitative mid-infrared spectroscopy. *Applied Spectroscopy*. 46:959-965, 1992.
180. Scavini M, Day PW, Eaton RP. Long term implantation of a new programmable implantable insulin pump in two diabetic dogs. *Artificial Organs*. 16(5):518-522, 1992.
181. Robinson MR, Eaton RP, Haaland DM, Koepp GW, Thomas EV, Stallard BR, Robinson PL. Noninvasive glucose monitoring in diabetic patients, a preliminary evaluation. *Clinical Chemistry*. 38:1618-1622, 1992.
182. Haaland DM, Robinson MR, Koepp GW, Thomas EV, Eaton RP. Reagentless near-infrared determination of glucose in whole blood using multivariate calibration. *Journal of Applied Spectroscopy*. 46:1575-1578, 1992.
183. MacKerrow SD, Osborn LA, Levy H, Eaton RP, and Economou P. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. *Annals of Internal Medicine*. 117:1014-1015, 1992.

1993:

184. Eaton RP, Bicknell JM, Griffey RH, King MK, Sibbitt RR, and Sibbitt WL, Jr. Sural nerve water in vivo in normal humans measured by magnetic resonance spectroscopy: relation to age, height, gender, and neurological profile. *Muscle & Nerve*. 16:307-311, 1993.

1994:

185. Bicknell JM, King MK, Eaton RP, Sibbitt WL. Neuropathic symptoms, neurologic examination deficits are present in a healthy volunteer population and increase with age. *International Journal of Diabetes*. 2:77-85, 1994.

186. Petropoulos H, Koechner D, Eaton RP, Hart BL and Brooks WM. Exponential filters to extract small structures in noisy images. *Proceedings, 1994 IEEE Seventh Symposium on Computer-Based Medical Systems*. p. 329-334.
187. Griffey RH, Sibbitt WL, Sibbitt RR, Jr., Griffey BV, Eaton RP, Hunsaker LA, and Vander Jagt DL. Polyol and water accumulation in muscle of galactose-fed rats. *Biochemical Pharmacology*. 48:1839-1841, 1994.

1995:

188. Eaton RP, Ferries LM, and Bickelman C. Impotence in a body builder related to anabolic steroid exposure: Response to clomiphene citrate. *The Western Journal of Medicine*. February: 158-160, 1995.
189. Eaton RP. Academic medical research in the twenty-first century: Will collaboration with industry and national laboratories be its savior? *The Pharos of alpha Omega alpha Honor Medical Society*. 58(4): 2-4, 1995.
190. Hart BL, and Eaton RP. Images of Clinical Medicine. Osmotic myelinolysis. *New England Journal of Medicine*. 333:1259, 1995
191. Koechner D, Petropoulos H, Eaton RP, Hart BL and Brooks WM. Segmentation of small structures in noisy images: semi-automated tissue hydration measurement. *Journal of Magnetic Resonance Imaging*. 5: 347-351, 1995.

1996:

192. Ratliff DM, VanderJagt DJ, Eaton RP, and Vanderjagt DL. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin dependent diabetic patients with diabetic complications: Aldose reductase, Glyoxalase I and Glyoxalase II - A Clinical Research Center Study. *Journal of Clinical Endocrinology & Metabolism*. 81(2):488-492, 1996.
193. Eaton RP, Qualls C, Bicknell J, Sibbitt WL Jr., King MK, and Griffey RH. Structure-function relationships within peripheral nerves in diabetic neuropathy: the hydration hypothesis. *Diabetologia*, 39(4):439-446, 1996.
194. Scavini M, Reich S, Eaton RP, Charles MA, and Dunn FL. Use of an integrated sideport for diagnosis and management of decreased flow rates in a programmable implanted insulin delivery system. Implantable Insulin Pump Trial Study Group. *Artificial Organs*. 20(9):991-6, 1996.
195. Dorin RI, Field JC, Boyle PJ, Eaton RP, Icenogle MV. Insulin resistance limits glucose utilization and exercise tolerance in myophosphorylase deficiency (McArdle's disease). *Journal of Applied Physiology*. 81(3): 1273-1278, 1996.

1997:

196. Scavini M, Reich S, Eaton RP, Charles A, Dunn FL. Catheter Survival during long-term insulin therapy with an implanted programmable pump. *Diabetes Care* 20:610-613, 1997.
197. Burge MR, Lanzi RA, Skarda ST, Eaton RP. Idiopathic hypogonadotropic hypogonadism in a male runner is reversed by clomiphene citrate. *Fertility and Sterility* 67:783-785, 1997.
198. Sibbitt WL, Jr., Eaton RP. Corticosteroid-responsive tenosynovitis is a common pathway for limited joint mobility in the diabetic hand. *Journal of Rheumatology*. 24: 1997.

1998:

199. Eaton RP, Dorin RI, Sibbitt W, Shah VO, Zager PG, and Bicknell J. A commentary on ten years of aldose reductase inhibition for limited joint mobility in diabetes. *Journal of Diabetes and its Complications* 12:34-38, 1998.

200. Eaton, RP and Conway M. Insulin Management in IDDM. Editor: W. Meikle, 1998.
201. Alam MK, Franke JE, Niemczyk TM, Maynard JD, Rohrscheib MR, Robinson MR, and Eaton RP. Characterization of pH Variation in Lysed Blood by Near-Infrared spectroscopy. *Applied Spectroscopy* 52: March 1998.
202. Shah VO, Scavini M, Nikolic J, Sun Y, Vai S, Griffith JK, Dorin RI, Stidley C, Yacoub M, Vander Jagt DL, Eaton RP, Zager PG. Z-2 Microsatellite Allele is Linked to Increased Expression of the Aldose Reductase Gene in Diabetic Nephropathy. *Journal of Clinical Endocrinology & Metabolism*. 83:2886-2891, 1998.